Alcon Patanase chemistry issues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alcon is testing a modified formulation of its pending olopatadine nasal spray Patanase after receiving "correspondence from…FDA requiring that the current formulation of the drug be modified to reduce or remove one of the inactive ingredients it contains before Patanase nasal spray can be approved," Alcon says Nov. 7. The company previously had indicated it expected such a request. The Patanase NDA for seasonal allergic rhinitis was submitted in December 2004; Patanase contains the same active ingredient as the firm's allergic conjunctivitis treatment Patanol...
You may also be interested in...
Alcon refiles NDA for Patanase
After pulling its Patanase (olopatadine) nasal spray NDA in November 2005, Alcon resubmits the application with an amendment to modify its formulation. The amendment includes six-month data from an agreed-upon study requested by FDA to remove or reduce one of the inactive ingredients (1Pharmaceutical Approvals Monthly November 2005, In Brief). The pending NDA seeks approval of the ophthalmic solution, which has the same active ingredient as the firm's Patanol ophthalmic solution, for treatment of allergic rhinitis...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.